Strategic partnerships PharmApprove operates as an integrated extension of SSI Strategy, offering high-stakes meeting preparation, scientific support, and data visualization. This positions the company to upsell broader strategic communications and regulatory affairs services to biotech and pharmaceutical clients already engaged with SSI Strategy.

Regulatory readiness With a focus on FDA and EMA meetings and 25+ years of experience serving over 200 clients, there is a clear opportunity to approach smaller biotech firms developing potentially disruptive therapies that require polished regulatory narratives and meeting preparedness.

Lifecycle expansion PharmApprove’s integration of project management, scientific support, and data visualization enables cross-sell into existing client programs, aligning well with life-cycle services such as regulatory strategy, clinical communications, and post-market pharmacovigilance.

Tech-enabled casework Utilizing a tech stack that includes OpenAI, analytics, and visualization capabilities suggests the ability to offer scalable, repeatable processes for preparing compelling regulatory pitches, which can be packaged into subscription or retainer models for clients seeking ongoing readiness.

Growth through acquisition Recent and historical SSI Strategy acquisitions indicate a culture of expanding capabilities; this creates opportunities to approach current clients of acquired firms (NDA Group, Fiore Healthcare Advisors, etc.) with PharmApprove’s tailored high-stakes meeting services as a targeted add-on.